Kate Rochlin

Kate Rochlin

Company: IN8Bio

Job title: Chief Operating Officer


Mastermind Session: How Can We Achieve Potency & Durability of Response for More Successful Clinical Outcomes? 10:30 am

Discussing why, when compared to the autologous approach, allogeneic therapies are experiencing major issues with durability Investigating reactivation of endogenous immunity from the patient donor’s immunity following allogeneic T-cell infusion Exploring the balance between long-lasting persistence versus the efficacy of the transient allogeneic product Discussing innovations in design and administration to develop a long acting…Read more

day: Advancing Durability & Persistence Focus Day

Allogeneic Gamma-Delta T Cell Therapies – Advancing Clinical Data in Phase 1 & Navigating the Path to Solid Tumor Applications 10:00 am

Overview of Gamma-delta T cells and their advantages in the Allogeneic setting Update on Allogeneic INB-100 clinical program, evaluating the safety, efficacy and patient response using gamma-delta T cells for Leukemia How to move beyond Leukemias and into solid tumors using Allogeneic Gamma-Delta T cell therapies, how to think about safety, durability and responseRead more

day: Day One

A Hanson Wade Group Company

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.